LB Pharmaceuticals Inc Common Stock

Healthcare

NASDAQ:LBRX · NASDAQ Global Select

Market Cap $814.99M Beta 0.71 P/E (TTM) -20.5

$28.42 -0.42%

-$0.12 today

52W Low $13.36High $33.47

Vol 0.16M · Avg 0.24M

EPS (TTM)-$1.39

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-8.4%

avg 31.6%

ROIC

-9.9%

avg -75.0%

ROA

-8.1%

avg -69.2%

Analysis

ROA is currently the strongest return metric at -8.1% versus its period average of -69.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management

Name	Title	Compensation	Tenure	Age	Shares Owned	Ownership %
Heather D. Turner	Chief Executive Officer & Director	$1.02M	—	53	—	—
Soffer	Chief Operating & Business Officer	$644,801.00	—	49	—	—
Anna Eramo	Chief Medical Officer	$616,933.00	—	51	—	—
Zachary Prensky	Co-founder, Advisor to the Chief Executive Officer & Director	$13,716.00	—	50	—	—
James Rawls	Senior Vice President of Regulatory Affairs	—	—	—	—	—
Richard Silva	Senior Vice President of Technical Operations	—	—	58	—	—
Marc L. Panoff	Senior Vice President of Finance	—	—	56	—	—
Ellen Rose	Senior Vice President of Corporate Affairs	—	—	—	—	—
Kaya Pai Panandiker	Chief Commercial Officer	—	—	49	—	—
Lindsay Beaupre	Senior VP of People & Culture	—	—	—	—	—
Minako Pazdera	General Counsel	—	—	—	—	—